Latest & greatest articles for cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cancer

11201. Influence of oral contraceptives in the development of post-molar trophoblastic neoplasia: a systematic review

Influence of oral contraceptives in the development of post-molar trophoblastic neoplasia: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 DARE.

11202. The effectiveness of treatment for depression/depressive symptoms in adults with cancer: a systematic review

The effectiveness of treatment for depression/depressive symptoms in adults with cancer: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 DARE.

11203. Efficacy of homeopathic therapy in cancer treatment

Efficacy of homeopathic therapy in cancer treatment Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 DARE.

11204. Randomized evidence on chemotherapy and hormonal therapy regimens for advanced endometrial cancer: an overview of survival data

Randomized evidence on chemotherapy and hormonal therapy regimens for advanced endometrial cancer: an overview of survival data Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 DARE.

11205. Second-line treatment for advanced non-small cell lung cancer: a systematic review

Second-line treatment for advanced non-small cell lung cancer: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 DARE.

11206. Menopausal hormone therapy (HT) in patients with breast cancer

Menopausal hormone therapy (HT) in patients with breast cancer Menopausal hormone therapy (HT) in patients with breast cancer Menopausal hormone therapy (HT) in patients with breast cancer Batur P, Blixen C E, Moore H C, Thacker H L, Xu M CRD summary This review examined the effects of menopausal hormone therapy on cancer reoccurrence, cancer mortality and overall mortality in patients with breast cancer. The authors concluded that hormone therapy is not associated with an increased incidence (...) of these outcomes. However, the reliability of this conclusion is limited by combining the results from studies of varying design. Authors' objectives To assess the effect of menopausal hormone therapy (HT) on cancer reoccurrence, cancer-related mortality and overall mortality in patients with a diagnosis of breast cancer. Searching MEDLINE, CINAHL and HealthSTAR were searched from 1967 to 2001; the search terms were given. In addition, existing reviews were used to identify references and conference

2006 DARE.

11207. The impact of treatment for gynecological cancer on health-related quality of life (HRQoL): a systematic review

, disease stage, route of treatment administration and HRQoL; and, in general, more detailed reporting and analysis of intervention studies. Bibliographic details Jones G L, Ledger W, Bonnett T J, Radley S, Parkinson N, Kennedy S H. The impact of treatment for gynecological cancer on health-related quality of life (HRQoL): a systematic review. American Journal of Obstetrics and Gynecology 2006; 194(1): 26-42 PubMedID DOI Indexing Status Subject indexing assigned by NLM MeSH Chemotherapy, Adjuvant (...) The impact of treatment for gynecological cancer on health-related quality of life (HRQoL): a systematic review The impact of treatment for gynecological cancer on health-related quality of life (HRQoL): a systematic review The impact of treatment for gynecological cancer on health-related quality of life (HRQoL): a systematic review Jones G L, Ledger W, Bonnett T J, Radley S, Parkinson N, Kennedy S H CRD summary Given the substantial methodological flaws and missing data in primary studies

2006 DARE.

11208. Gender and race/ethnicity affect the cost-effectiveness of colorectal cancer screening

(-below for bibliographic details). The time horizon was 35 years. No further details on the modelling approach used were reported in the present paper. Outcomes assessed in the review The parameters included in the model for the natural history of the disease were: the prevalence of adenomas at age 50; the proportion of all clinically detected cancers that begin as polyps; years required for a 5-mm adenoma to progress to CRC and for a new invasive cancer to progress to late-stage cancer; years before (...) perforation of the large bowel, colonoscopy-induced mortality, and surgery-related mortality in patients with CRC. Study designs and other criteria for inclusion in the review Data on cancer cases were derived from medical records from the California Cancer Registry from 1988 - 1995. Such data included demographic data such as age, gender, race or ethnicity (white, black, Latino or Asian), pathology of the disease, site and stage of disease, treatment during the first 4 months and survival status

2006 NHS Economic Evaluation Database.

11209. Genetic nurse counsellors can be an acceptable and cost-effective alternative to clinical geneticists for breast cancer risk genetic counselling: evidence from two parallel randomised controlled equivalence trials

Genetic nurse counsellors can be an acceptable and cost-effective alternative to clinical geneticists for breast cancer risk genetic counselling: evidence from two parallel randomised controlled equivalence trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 NHS Economic Evaluation Database.

11210. Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer

Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 NHS Economic Evaluation Database.

11211. Economic impact of screening for bladder cancer using bladder tumor markers: a decision analysis

analysis was performed. Implications of the study The study results suggest that the use of NMP22 for bladder cancer screening might be cost-effective in appropriately selected high-risk patients. Further studies should be undertaken to assess the accuracy of bladder tumour markers in detecting bladder cancer in a completely asymptomatic cohort. Source of funding None stated. Bibliographic details Svatek R S, Sagalowsky A I, Lotan Y. Economic impact of screening for bladder cancer using bladder tumor (...) cancer screening and surveillance. Urol Nurs 2004;24:171-2. Indexing Status Subject indexing assigned by NLM MeSH Aged; Aged, 80 and over; Biomarkers, Tumor /analysis; Costs and Cost Analysis; Humans; Middle Aged; Nuclear Proteins /analysis; Sensitivity and Specificity; Urinary Bladder Neoplasms /diagnosis /economics AccessionNumber 22006001553 Date bibliographic record published 31/01/2007 Date abstract record published 31/01/2007 NHS Economic Evaluation Database (NHS EED) Produced by the Centre

2006 NHS Economic Evaluation Database.

11212. The cost of prostate cancer chemoprevention: a decision analysis model

-term clinical and economic impact of chemoprevention with finasteride, compared with no preventive treatment, in a hypothetical cohort of men aged 50 years. The men were assumed to receive the intervention drug for 20 years or until PC was diagnosed. The simulation considered progression in a fixed sequence of health states: cancer-free, PC (Gleason grades 8 - 10, 7, 6, or 2 - 5), biochemical recurrence of PC, metastatic disease and death. A graphical representation of the model was provided (...) . At the end of each cycle, patients could remain in the same state, progress to a more advanced stage, or die of unrelated causes. Patients diagnosed with cancer received immediate radical retropubic prostatectomy and pelvic lymph node dissection (without adjuvant or neoadjuvant therapy). Biochemical recurrence was managed initially with watchful waiting. Patients who entered the metastatic disease health state were assumed to be treated with androgen ablation therapy using leuprolide acetate. Outcomes

2006 NHS Economic Evaluation Database.

11213. Cytoprotective effect of amifostine in the treatment of childhood neoplastic diseases: a clinical study including the pharmacoeconomic analysis

and/or anthracyclins as a cytoprotector in the treatment of children with neoplastic diseases. The dose used was 910 mg/m2. Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis. Study population The study population comprised children treated for solid tumours and acute nonlymphoblastic leukaemias (ANLL). Setting The setting was secondary care. The economic study was carried out in Lodz, Sporna (Poland). Dates to which data relate The effectiveness and resource use evidence (...) of childhood neoplastic diseases: a clinical study including the pharmacoeconomic analysis. Pharmacological Reports 2006; 58(1): 30-34 PubMedID Other publications of related interest Bennet CL, Lane D, Stinson T, Glatzel M, Buntzel J. Economic analyses of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany. Cancer Invest 2001;19:107-13. Calhoun EA, Bennet CL. Pharmacoeconomics of amifostine in ovarian

2006 NHS Economic Evaluation Database.

11214. Cost-effectiveness analysis of colorectal cancer screening with stool DNA testing in intermediate-incidence countries

Cost-effectiveness analysis of colorectal cancer screening with stool DNA testing in intermediate-incidence countries Cost-effectiveness analysis of colorectal cancer screening with stool DNA testing in intermediate-incidence countries Cost-effectiveness analysis of colorectal cancer screening with stool DNA testing in intermediate-incidence countries Wu G H, Wang Y W, Yen A M, Wong J M, Lai H C, Warwick J, Chen T H Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The present study compared screening strategies for the early identification of colorectal cancer (CRC). Specifically, it compared 3-, 5- and 10-yearly stool deoxyribonucleic acid (DNA) testing (DNA3, DNA5 and DNA10), with annual faecal occult blood testing (FOBT1), 5

2006 NHS Economic Evaluation Database.

11215. Pharmacoeconomic aspects of adjuvant anastrozole or tamoxifen in breast cancer: a Slovenian perspective Full Text available with Trip Pro

BE. Cost-effectiveness projections of anastrozole vs tamoxifen as initial adjuvant therapy in ER-positive breast cancer. Breast 2003;12:S44-5. Mansel R. Cost-utility analysis of anastrozole versus tamoxifen as adjuvant therapy in post-menopausal women with early breast cancer: a UK National Health Service perspective. Ann Oncol 2004;15 Suppl 3:65. Indexing Status Subject indexing assigned by NLM MeSH Antineoplastic Agents, Hormonal /therapeutic use; Breast Neoplasms /drug therapy /economics /therapy (...) ; Chemotherapy, Adjuvant; Combined Modality Therapy; Cost-Benefit Analysis; Decision Trees; Disease-Free Survival; Economics, Pharmaceutical; Humans; Neoplasm Recurrence, Local /drug therapy /economics /therapy; Neoplasms, Hormone-Dependent /drug therapy /economics; Nitriles /therapeutic use; Slovenia; Tamoxifen /therapeutic use; Treatment Outcome; Triazoles /therapeutic use AccessionNumber 22006001807 Date bibliographic record published 26/09/2006 Date abstract record published 23/12/2008 NHS Economic

2006 NHS Economic Evaluation Database.

11216. Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: a cost-effectiveness analysis Full Text available with Trip Pro

Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: a cost-effectiveness analysis Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: a cost-effectiveness analysis Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: a cost-effectiveness analysis Rocconi R P, Case A S, Straughn J M, Estes J M, Partridge E E Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined several strategies for the treatment of women with recurrent platinum-resistant epithelial ovarian cancer (EOC): best supportive care (BSC) including hospice or palliative care; second-line

2006 NHS Economic Evaluation Database.

11217. Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis

Cancer Trialists' Collaboration Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717. Indexing Status Subject indexing assigned by NLM MeSH Analysis of Variance; Antineoplastic Agents, Hormonal /administration & Antineoplastic Combined Chemotherapy Protocols /economics /therapeutic use; Aromatase Inhibitors /administration & Breast Neoplasms /drug therapy /economics /mortality (...) ; Canada; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease-Free Survival; Female; Humans; Neoplasm Recurrence, Local /prevention & Nitriles /administration & Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk Reduction Behavior; Sensitivity and Specificity; Survival Rate; Tamoxifen /administration & Time Factors; Treatment Outcome; Triazoles /administration & control; dosage /economics; dosage /economics; dosage /economics; dosage /economics; dosage /economics

2006 NHS Economic Evaluation Database.

11218. Influence of prolonged use of intravenous administration sets in paediatric cancer patients on CVAD-related bloodstream infection rates and hospital resources

Influence of prolonged use of intravenous administration sets in paediatric cancer patients on CVAD-related bloodstream infection rates and hospital resources Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 NHS Economic Evaluation Database.

11219. The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer Full Text available with Trip Pro

-analyses that compared capecitabine or tegafur-uracil with 5-FU/LV regimens as first-line treatment for metastatic CRC were included. The keywords used in the search included colorectal, colon, rectum, neoplasm, carcinoma, adenocarcinoma, capecitabine, Xeloda, fluoropyrimidine, tegafur, Uftoral. Sources searched to identify primary studies Sources such as Cancerlit, the Cochrane Library, MEDLINE and EMBASE were searched for primary studies. The reference lists of relevant articles were (...) The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer Ward S E, Kaltenthaler E, Cowan J, Marples M, Orr B, Seymour M T Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS

2006 NHS Economic Evaluation Database.

11220. Covered metal versus plastic stents for malignant common bile duct stenosis: a prospective, randomized, controlled trial

Covered metal versus plastic stents for malignant common bile duct stenosis: a prospective, randomized, controlled trial Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 NHS Economic Evaluation Database.